SEC Tracker
Get the app
ANAB · XBRL financial data

Anaptysbio financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ANAB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers3,3189,005*7,17910,97130,01743,113*27,77122,26376,320108,249*25,55627,488*
Research and development30,878—37,04241,99742,212—41,18037,82431,407———
General and administrative10,17210,276*12,3389,29510,56210,194*14,13010,60910,20915,789*26,202(2,812)*
Total operating expenses41,05051,140*49,38051,29252,77452,783*55,31048,43341,61641,348*60,193(39,471)*
Operating income (loss)(37,732)(42,135)*(42,201)(40,321)(22,757)(9,670)*(27,539)(26,170)34,70466,901*(34,637)66,959*
Other income (expense)1(2)*(2)0(5)21*1,9023,5310(3)*(1)0*
Income tax expense (benefit)0(4)*090(6)*4439081*40(181,491)*
Net income (loss)(37,308)(42,211)*(43,936)(46,660)(32,851)(21,784)*(39,329)(38,630)15,11349,614*(52,884)183,880*
Earnings per share, basic USD per share(1.41)(1.59)*(1.64)(1.71)(1.14)(0.72)*(1.28)(1.34)0.54—(1.84)—
Earnings per share, diluted USD per share(1.41)(1.59)*(1.64)(1.71)(1.14)(0.72)*(1.28)(1.34)0.52—(1.84)—
Weighted average shares, basic thousands of shares26,54626,587*26,80127,35628,89330,450*30,64428,81027,83327,787*28,691—
Weighted average shares, diluted thousands of shares26,54626,587*26,80127,35628,89330,450*30,64428,81029,01826,602*28,691—

Balance sheet

CSV

Fiscal quarters (ANAB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,29535,96553,69571,821191,581123,08098,63744,298109,833238,196248,469133,826
Marketable securities386,752354,939300,970278,983238,536262,293241,299221,412139,12373,44237,98630,317
Marketable securities, non-current40,20327,02615,47342,64627,91435,47043,02127,9967,6980—0
Prepaid and other current assets11,6849,08010,6667,5396,3695,7385,2924,7786,0094,7623,9078,650
Total current assets428,000406,835372,420367,350448,681431,876363,112291,906330,650350,250316,109198,427
Property and equipment, net2,2542,0981,9541,8331,7281,8491,7411,6281,5001,3701,280102
Right-of-use asset16,61316,17415,73215,29114,83914,38313,92313,46412,99412,51912,03911,560
Total assets487,326452,389405,835427,376493,418483,834422,053335,250353,098364,395329,684316,984
Accounts payable6,5214,6984,5824,8903,5924,0026,1233,3292,8933,8717,5174,394
Accrued liabilities30,91630,96725,90333,68038,40139,50135,95230,19733,17132,67432,06528,798
Total current liabilities39,17837,44232,29840,42043,88045,42844,03735,52738,10438,62541,70235,353
Lease liability, non-current16,49316,03715,57515,09614,60714,11213,61313,09512,56612,03211,49310,934
Accumulated deficit(571,885)(614,096)(658,032)(704,692)(737,543)(759,327)(798,656)(837,286)(822,173)(772,559)(825,443)(641,563)
Total stockholders' equity120,38388,10347,7789,87984,36770,86834,021(44,733)(29,416)37,21012,74710,585
Total liabilities and equity487,326452,389405,835427,376493,418483,834422,053335,250353,098364,395329,684316,984
Common shares outstanding (cover page) thousands of shares26,57526,76327,31927,44930,42930,66729,38027,99727,68828,74829,10129,895

Cash flows

CSV

Fiscal quarters (ANAB's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(37,308)(42,211)*(43,936)(46,660)(32,851)(21,784)*(39,329)(38,630)15,11349,614*(52,884)183,880*
Stock-based compensation7,807*8,111*10,1317,544*8,189*8,184*9,1709,239*9,157*8,506*14,218(5,898)*
Depreciation and amortization158*165*163154*144*145*146142*140*131*130(121)*
Net cash from operating activities(36,474)*(34,349)*(37,253)(21,322)*(10,090)*(66,672)*(10,700)(40,244)*(27,356)*97,997*(25,919)(26,640)*
Purchases of property and equipment162*280*2733*35*263*3539*12*1*17—
Net cash from investing activities30,635*49,178*68,616(2,442)*58,620*(29,396)*14,84736,403*103,282*73,500*34,9837,562*
Proceeds from issuing common stock160*264*811979*4,128*555*2901,423*336*12,212*14,02111,350*
Share repurchases0*0*00*0*456*4,42451,098*9,720*3,384*00*
Net cash from financing activities(3,072)*(5,159)*(13,633)41,890*71,230*27,567*(28,590)(50,498)*(10,391)*(43,134)*1,209(95,565)*
Net change in cash(8,911)*9,670*17,73018,126*119,760*(68,501)*(24,443)(54,339)*65,535*128,363*10,273(114,643)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Anaptysbio133,82627,488*(26,640)*29.9M6.2 quarters 10-KTJun 30, 2026
Amphastar Pharmaceuticals223,614183,90351,324*42.5M— 10-QJun 30, 2026
Stoke Therapeutics107,27111,255(62,686)*65.4M5.2 quarters 10-QSep 30, 2026
Trevi Therapeutics54,302not reported(17,429)*142.5M18.3 quarters 10-QJun 30, 2026
ImmunityBio75,67051,240(66,494)*1.1B5.4 quarters 10-QJun 30, 2026
Anavex Life Sciences118,326not reported(9,096)*92.7M13.0 quarters 10-QJun 30, 2026
Evolus45,17084,084(3,587)*66.1M12.6 quarters 10-QJun 30, 2026
Xencor44,66351,221(55,658)*74.4M6.8 quarters 10-QJun 30, 2026
Immunome217,7060(61,692)*113.6M8.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.